Summary
A capsule preparation containing small, enteric-coated granules of digoxin was developed to prevent acid hydrolysis of the drug in the stomach and to diminish the variation in plasma glycoside concentration during the intervals between doses. The absorption and metabolism of tritiated digoxin after a single oral loading dose of this formulation (Formulation C) were compared to those after ingestion of a digoxin solution (Formulation S) by 8 healthy men. Drug concentrations were measured by radioimmunoassay (RIA) and liquid chromatography (LC). The percentage of the digoxin dose excreted in the urine during 72 h, as measured by RIA, was significantly lower after the capsule (20.5±2.0% vs 36.2±3.0% after S, mean±SEM) but total urinary radioactivity after the two treatments was similar (C 35.3±5.2 and S 41.2±2.6%; p>0.05). The discrepancy was mainly due to significantly greater excretion of dihydrodigoxin after the capsule (\(\bar m\) 12.8%, range 0–28.6% of the dose) than after the digoxin solution (\(\bar m\) 5.4%, range 0–14.5%). Dihydrodigoxin was not measured by the RIA. The recovery of hydrolysis metabolites (LC) was greater during the first 24 h after S (2.3±0.6% vs 0.9±0.3% after C; p<0.05). The peak plasma concentration of digoxin (RIA) was significantly reduced and delayed after intake of C (2.5±0.4 nmol/l at 3.8±0.3 h vs. 8.3±0.8 nmol/l at 0.9±0.1 h after S), and so was the shortening of electromechanical systole at 1.5 h, 2.5 h, and 3 h. Thus, the enteric-coated digoxin preparation delayed the absorption and reduced the hydrolysis of the glycoside, but it also carried the drawback of reducing digoxin availability, mainly because of increased metabolism to dihydrodigoxin.
Similar content being viewed by others
References
Alpsten M, Bogentoft C, Ekenved G, Sölvell L (1979) On the disintegration of hard gelatine capsules in fasting volunteers using a profile scanning technique. J Pharm Pharmacol 31: 480–481
Bergdahl B, Bogentoft C, Jonsson UE, Magnusson JO (1980) Absorption of digoxin from a new microencapsulated formulation. Eur J Clin Pharmacol 17: 443–447
Bergdahl B, Bogentoft C, Jonsson UE, Magnusson JO (1983) Fasting and postprandial absorption of digoxin from a microencapsulated formulation. Eur J Clin Pharmacol 25: 207–210
Bertler B, Redfors A, Medin S, Nyberg L (1972) Bioavailability of digoxin. Lancet 2: 708
Brown BT, Stafford A, Wright SE (1962) Chemical structure and pharmacological activity of some derivatives of digitoxigenin and digoxigenin. Br J Pharmacol 18: 311–324
Butler VP, Tse-Eng D, Lindenbaum J, Kalman SM, Peibisz JJ, Rund DG, Wissel PS (1982) The development and application of a radioimmunoassay for dihydrodigoxin, a digoxin metabolite. J Pharmacol Exp Ther 221: 123–131
Caste MC (1975) Isolation and quantitation of picomole quantities of digoxin, digitoxin and their metabolites by high pressure liquid chromatography. J Chromatogr 115: 437–445
Clark DR, Kalman SM (1974) Dihydrodigoxin: a common metabolite of digoxin in man. Drug Metab Dispos 2: 148–150
Dobkin JF, Saha JR, Butler VP, Neu HC, Lindenbaum J (1983) Digoxin-inactivating bacteria: identification in human gut flora. Science 220: 325–327
Doherty JE, Flanigan WJ, Murphy ML, Bulloch RT, Dalrymple GV, Beard OW, Perkins WH (1970) Tritiated digoxin XIV. Enterohepatic circulation, absorption and excretion studies in human volunteers. Circulation 42: 867–873
Doherty JE, Kane JJ (1975) Clinical pharmacology of digitalis glycosides. Ann Rev Med 26: 159–171
Eriksson BM, Tekenbergs L, Magnusson JO, Molin L (1981) Determination of tritiated digoxin and metabolites in urine by liquid chromatography. J Chromatogr 223: 401–408
Gault MH, Charles JD, Sugden DL, Kepkay DC (1977) Hydrolysis of digoxin by acid. J Pharm Pharmacol 29: 27–32
Gault MH, Sugden D, Maloney C, Ahmed M, Tweeddale M (1979) Biotransformation and elimination of digoxin with normal and minimal renal function. Clin Pharmacol Ther 25: 499–513
Gault H, Kalra J, Ahmed M, Kepkay D, Barrowman J (1980) Influence of gastric pH on digoxin biotransformation. I: Intragastric hydrolysis. Clin Pharmacol Ther 27: 16–21
Gibson TP, Nelson HA (1980) The question of cumulation of digoxin metabolites in renal failure. Clin Pharmacol Ther 25: 219–223
Greenblatt DJ, Smith TW, Koch-Weser J (1976) Bioavailability of drugs: the digoxin dilemma. Clin Pharmacokinet 1: 36–51
Greenwood H, Snedden W, Hayward RP, Landon J (1975) The measurement of urinary digoxin and dihydrodigoxin by radioimmunoassay and mass spectroscopy. Clin Chim Acta 62: 213–224
Iisalo E (1977) Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 2: 1–16
Kramer WG, Kinnear NL, Morgan K (1978) Variability among commercially available digoxin radioimmunoassay kits in cross reactivity to dihydrodigoxin. Clin Chem 24: 155–157
Lindenbaum J, Rund D, Butler VP, Tse-Eng D, Saha JR (1981a) Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 305: 789–794
Lindenbaum J, Tse-Eng D, Butler VP, Rund DG (1981b) Urinary excretion of reduced metabolites of digoxin. Am J Med 71: 67–74
Loo JC, McGilveray IJ, Jordan N (1977) Quantitation of digoxigenin in serum following oral administration of digoxin in humans. Res Commun Chem Pathol Pharmacol 17: 497–506
Luchi RL, Gruber JW (1968) Unusually large digitalis requirements. A study of altered digoxin metabolism. Am J Med 45: 322–328
Magnusson JO, Bergdahl B, Bogentoft C, Jonsson UE, Tekenbergs L (1982a) Excretion of digoxin and its metabolites in urine after a single oral dose in healthy subjects. Biopharm Drug Disposit 3: 211–218
Magnusson JO, Bergdahl B, Bogentoft C, Jonsson UE (1982b) Metabolism of digoxin and absorption site. Br J Clin Pharmacol 14: 284–285
Magnusson JO (1983) Metabolism of digoxin after oral and intrajejunal administration. Br J Clin Pharmacol 16: 741–742
Magnusson JO, Bergdahl B, Gustafsson S (1984) Urinary excretion of digoxin and its metabolites in hyperacidic patients and in patients during coronary care. Arzneimittelforsch (Drug Res) 34: 87–89
Manninen V, Reissell P, Pankkala E (1976) Transient cardiac arrhythmias after single oral daily maintenance doses of digoxin. Clin Pharmacol Ther 20: 266–268
McGilveray IJ, Loo JCK, Jordan N, Wattel S, Ruedy J (1979) Digoxin dosage in patients with gastric hyperacidity. Can Med Assoc J 121: 704–705
Molin L, Dahlström G, Nilsson MI (1983) Solubility, partition, and adsorption of digitalis glycosides. Acta Pharm Suec 20: 129–144
Okarma TB, Tramell P, Kalman SM (1972) The surface interaction between digoxin and cultured heart cells. J Pharmacol Exp Ther 183: 559–576
Peters U, Falk LC, Kalman SM (1978) Digoxin metabolism in patients. Arch Intern Med 138: 1074–1076
Redfors A (1972) Plasma digoxin concentration — its relation to digoxin dosage and clinical effects in patients with atrial fibrillation. Br Heart J 34: 383–391
Sternson LA, Shaffer RD (1978) Kinetics of digoxin stability in aqueous solution. J Pharm Sci 67: 327–330
Stoll RG, Christiansen MS, Sakmar E, Wagner JG (1972) The specificity of digoxin radioimmunoassay procedure. Res Commun Chem Pharmacol 4: 503–510
Weissler AM, Harris WS, Schoefeld CD (1969) Bedside technics for the evaluation of ventricular function in man. Am J Cardiol 23: 577–583
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Magnusson, J.O., Bergdahl, B., Bogentoft, C. et al. Increased metabolism to dihydrodigoxin after intake of a microencapsulated formulation of digoxin. Eur J Clin Pharmacol 27, 197–202 (1984). https://doi.org/10.1007/BF00544045
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544045